PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
Proprotein convertase subtilisin/kexin type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C) , is raised in hepatocytes and released into plasma where it binds to LDL receptors (LDLR), leading to their cleavage. PCSK9 adheres to the epidermal growth factor-like repeat A...
Main Authors: | Saeideh Sobati, Amir Shakouri, Mahdi Edalati, Daryoush Mohammadnejad, Reza Parvan, Javad Masoumi, Jalal Abdolalizadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2020-08-01
|
Series: | Advanced Pharmaceutical Bulletin |
Subjects: | |
Online Access: | https://apb.tbzmed.ac.ir/PDF/apb-10-502.pdf |
Similar Items
-
PCSK9 and cancer: Rethinking the link
by: Khadijeh Mahboobnia, et al.
Published: (2021-08-01) -
Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01) -
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01) -
<i>Acanthaster planci</i> Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
by: Nurjannatul Naim Kamaruddin, et al.
Published: (2021-08-01) -
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)